Coherus Continues Funding IO Ambitions By Offloading Biosimilars

 
• By Joseph Haas
  
Coherus sold off its Neulasta biosimilar to further focus on immuno-oncology (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Strategy